Kinase Inhibitors

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

By

Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.

Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients

Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients

By

Results from a sub-analysis of the impact of age on the safety and efficacy of lenvatinib in patients with RR-DTC in the SELECT trial showed that lenvatinib significantly increased PFS.

Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers

Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers

By

Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.

What Is The Optimal Sequencing of Novel Agents for CLL?

What Is The Optimal Sequencing of Novel Agents for CLL?

By

Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.

Combination Drug Therapy May Prevent Tumors From Sidestepping Kinase Inhibitors

By

New research has shed light on how some tumors continue their growth despite treatment with kinase inhibitors, and on how a combination of drugs can yield much better results.

Volasertib Demonstrates Antitumor Activity in Patients With Ovarian Cancer

By

A study compared the effectiveness of volasertib versus chemotherapy for treatment of platinum-resistant or -refractory ovarian cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs